Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)

NCT05618301 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Sickle Cell Disease

Interventions

DRUG: Motixafortide
DRUG: Natalizumab
PROCEDURE: Leukapheresis

Sponsor

Washington University School of Medicine

Collaborators

[object Object]
[object Object]
[object Object]